Pharmaceuticals Japan

Japan Pneumococcal Vaccines Market Analysis, 2024–2034

Japan Pneumococcal Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $653.5 Mn Estimated value
Estimate 2025 $694.7 Mn 6.9% of the global market
Projected 2034 $1.20 Bn 73.3% Adds $509.2 Mn over 9 forecast years
CAGR 2025–2034 6.3% Faster than 21% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 6.87% of the global market.
  • In APAC, the largest is China at $901.1 Mn.
  • Fastest growing: India at 9.1% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$509.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pneumococcal Vaccines Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $653.5 Mn — —
2025 (base) $694.7 Mn +$41.2 Mn —
2026 (forecast) $738.5 Mn +$43.8 Mn +6.3%
2027 (forecast) $785.0 Mn +$46.5 Mn +13%
2028 (forecast) $834.4 Mn +$49.5 Mn +20.1%
2029 (forecast) $887.0 Mn +$52.6 Mn +27.7%
2030 (forecast) $942.9 Mn +$55.9 Mn +35.7%
2031 (forecast) $1.00 Bn +$59.4 Mn +44.3%
2032 (forecast) $1.07 Bn +$63.1 Mn +53.4%
2033 (forecast) $1.13 Bn +$67.1 Mn +63%
2034 (forecast) $1.20 Bn +$71.4 Mn +73.3%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $10.11 Bn
  2. North America $5.62 Bn
  3. US $3.68 Bn
  4. APAC $1.99 Bn
  5. Europe $1.63 Bn
  6. Canada $923.1 Mn
  7. China $901.1 Mn
  8. Japan (this report) $694.7 Mn
  9. Latin America $489.7 Mn
  10. Germany $371.6 Mn
  11. Middle East $352.6 Mn
  12. Italy $260.9 Mn
  13. France $248.2 Mn
  14. UK $219.7 Mn
  15. Brazil $228.4 Mn
  16. India $202.2 Mn
  17. Saudi Arabia $195.2 Mn
  18. Ecuador $186.2 Mn
  19. Spain $175.3 Mn
  20. Mexico $167.1 Mn
  21. Africa $140.1 Mn
  22. Russia $111.2 Mn
  23. Australia $112.7 Mn
  24. New Zealand $109.6 Mn
  25. South Africa $74.1 Mn
  26. UAE $46.9 Mn
  27. Egypt $31.8 Mn
  28. Philippines $19.8 Mn
  29. Malaysia $18.4 Mn
  30. Hong Kong $17.6 Mn
  31. Thailand $12.2 Mn
  32. Singapore $11.2 Mn
  33. Kenya $7.2 Mn

The Japan Pneumococcal Vaccines Market Analysis Executive Summary

Pneumococcal vaccines protect against pneumonia, meningitis and blood infections caused by pneumococcus bacteria.

Key segments of the pneumococcal Vaccines market include type (Conjugate Vaccines and Polysaccharide Vaccines) and age (Infants, Older Adults and At-Risk Adults).

Japan Pneumococcal Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the pneumococcal Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the pneumococcal Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the pneumococcal Vaccines market.

Competitive Landscape for Pneumococcal Vaccines Market in Japan

The pneumococcal Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pneumococcal Vaccines Market in Japan

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pneumococcal Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pneumococcal Vaccines right now, from free public sources.

Clinical trials

2 active trials in Japan

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Pfizer Inc. 13 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Sanofi 7 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Sinovac Biotech Co., Ltd 5 active trials on ClinicalTrials.gov (opens in a new tab)
  4. CanSino Biologics Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Vaxcyte 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 657 papers since 2021 (worldwide)

  1. Comparative safety of the 20-valent and the 13-valent pneumococcal vaccines in infants and toddlers: a systematic review and meta-analysis of randomized trials. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 2026
  2. Comprehensive vaccination guidelines for patients with inborn errors of immunity: A European Society for Immunodeficiencies Consensus. The Journal of allergy and clinical immunology, 2026
  3. Automated deep learning tool for robust colony counting in vaccine immunogenicity bioassays. Bioanalysis, 2026
  4. Recent research on vaccines for older adults. Age and ageing, 2026
  5. Indian Multidisciplinary Expert Opinions on the Use of 20-Valent Pneumococcal Conjugate Vaccine in Adults. Vaccines, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pneumococcal Vaccines in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on Pneumococcal Vaccines are running in Japan?
2 studies are recruiting, active or about to start in Japan.[4]
How much research is published on Pneumococcal Vaccines?
PubMed lists 657 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Pneumococcal Vaccines in Japan? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Airway Management Devices: Critical Tools in EmergenciesKeeping the airway open is the first step in saving a life. More than half of deaths in low- and… Anaesthesia and Respiratory Devices: Lessons After COVIDMore than 5 billion people lack access to safe, affordable medical oxygen. COVID-19 exposed gaps in… Snoring and Sleep Apnoea Devices: Sleeping BetterAn estimated 936 million adults have obstructive sleep apnoea, and most are undiagnosed. CPAP machines, oral…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Japan

See all
Same topic, other categories

Related on vaccines and respiratory

See the topic